These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 27459621)

  • 1. [The new endothelin receptor antagonist macitentan: Prospects for therapy of pulmonary arterial hypertension].
    Avdeev SN
    Ter Arkh; 2016; 88(7):89-97. PubMed ID: 27459621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of macitentan for the treatment of pulmonary arterial hypertension.
    Selej M; Romero AJ; Channick RN; Clozel M
    Ann N Y Acad Sci; 2015 Nov; 1358():68-81. PubMed ID: 26291180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial.
    Jansa P; Pulido T
    Am J Cardiovasc Drugs; 2018 Feb; 18(1):1-11. PubMed ID: 29280064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience.
    Belge C; Delcroix M
    Ther Adv Respir Dis; 2019; 13():1753466618823440. PubMed ID: 30736726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
    Bedan M; Grimm D; Wehland M; Simonsen U; Infanger M; Krüger M
    Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):103-113. PubMed ID: 29719121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.
    Galiè N; Jansa P; Pulido T; Channick RN; Delcroix M; Ghofrani HA; Le Brun FO; Mehta S; Perchenet L; Rubin LJ; Sastry BKS; Simonneau G; Sitbon O; Souza R; Torbicki A
    Eur Heart J; 2017 Apr; 38(15):1147-1155. PubMed ID: 28329315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macitentan: a review of its use in patients with pulmonary arterial hypertension.
    Dhillon S
    Drugs; 2014 Sep; 74(13):1495-507. PubMed ID: 25060980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Macitentan in Patients With Eisenmenger Syndrome.
    Gatzoulis MA; Landzberg M; Beghetti M; Berger RM; Efficace M; Gesang S; He J; Papadakis K; Pulido T; Galiè N;
    Circulation; 2019 Jan; 139(1):51-63. PubMed ID: 30586694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macitentan: A Review in Pulmonary Arterial Hypertension.
    Keating GM
    Am J Cardiovasc Drugs; 2016 Dec; 16(6):453-460. PubMed ID: 27580996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macitentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension, does not affect cardiac repolarization in healthy subjects.
    Lindegger N; Sidharta PN; Reseski K; Dingemanse J
    Pulm Pharmacol Ther; 2014 Oct; 29(1):41-8. PubMed ID: 24813561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macitentan for the treatment of pulmonary arterial hypertension.
    DuBrock HM; Channick RN
    Expert Rev Respir Med; 2014 Aug; 8(4):393-9. PubMed ID: 24998329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macitentan for the treatment of pulmonary arterial hypertension.
    Kholdani CA; Fares WH; Trow TK
    Vasc Health Risk Manag; 2014; 10():665-73. PubMed ID: 25473292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelin research and the discovery of macitentan for the treatment of pulmonary arterial hypertension.
    Clozel M
    Am J Physiol Regul Integr Comp Physiol; 2016 Oct; 311(4):R721-R726. PubMed ID: 27534881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
    Sidharta PN; Krähenbühl S; Dingemanse J
    Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):437-49. PubMed ID: 25604973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New horizons for the use of the second generation of endothelin receptor antagonist macitentan in patients with pulmonary hypertension.
    Martynyuk TV; Nakonechnikov SN; Chazova IY
    Ter Arkh; 2018 Apr; 90(4):72-80. PubMed ID: 30701878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling of pharmacokinetics, efficacy, and hemodynamic effects of macitentan in patients with pulmonary arterial hypertension.
    Krause A; Zisowsky J; Dingemanse J
    Pulm Pharmacol Ther; 2018 Apr; 49():140-146. PubMed ID: 29501590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macitentan and morbidity and mortality in pulmonary arterial hypertension.
    Pulido T; Adzerikho I; Channick RN; Delcroix M; Galiè N; Ghofrani HA; Jansa P; Jing ZC; Le Brun FO; Mehta S; Mittelholzer CM; Perchenet L; Sastry BK; Sitbon O; Souza R; Torbicki A; Zeng X; Rubin LJ; Simonneau G;
    N Engl J Med; 2013 Aug; 369(9):809-18. PubMed ID: 23984728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial.
    Mehta S; Sastry BKS; Souza R; Torbicki A; Ghofrani HA; Channick RN; Delcroix M; Pulido T; Simonneau G; Wlodarczyk J; Rubin LJ; Jansa P; Hunsche E; Galiè N; Perchenet L; Sitbon O
    Chest; 2017 Jan; 151(1):106-118. PubMed ID: 27671974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
    Dingemanse J; Sidharta PN; Maddrey WC; Rubin LJ; Mickail H
    Expert Opin Drug Saf; 2014 Mar; 13(3):391-405. PubMed ID: 24261583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of a Novel Endothelin Receptor Antagonist, Macitentan, in Japanese Patients With Pulmonary Arterial Hypertension.
    Tahara N; Dobashi H; Fukuda K; Funauchi M; Hatano M; Ikeda S; Joho S; Kihara Y; Kimura T; Kondo T; Matsushita M; Minamino T; Nakanishi N; Ozaki Y; Saji T; Sakai S; Tanabe N; Watanabe H; Yamada H; Yoshioka K; Sasayama S
    Circ J; 2016 May; 80(6):1478-83. PubMed ID: 27180890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.